Previous 10 | Next 10 |
Defensive stocks are often misunderstood. In recent years, even when they have delivered strong and steady earnings, returns have disappointed. After a period of underperformance for defensives, a broadening market can represent real opportunity. Beyond utilities, we believe that ...
In any market’s upswing, there are always going to be people who make the case that “it’s different this time”, and historically, most of the time, that argument doesn’t hold up. I have never seen so many interesting and novel therapeutic opportuniti...
From a consumer perspective, the consumer is actually now demanding a focus on environmental, social, governance factors. If public expectations for inflation do rise, that is going to be a change from years past. There’s going to be an opportunity to make medical progress ...
Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good wa...
Health Canada approves Roche's (RHHBY) Accu-Chek Inform II Hospital Blood Glucose System system for Critically ill Care Use.With this new claim, healthcare professionals using the Accu-Chek Infor II System can continue to deliver accurate and reliable blood glucose me...
Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare
In January 2020, only 0.24% of total medical claims in the U.S. were telemedicine-related. One year later, they totaled 7%. It took 15 years for e-commerce penetration to rise from less than 1% to over 7%. The pandemic helped telemedicine do it in one. Population-wide immunity to ...
This has been a long, long boom in the amount of money that's flowed into this sector, and I don't think I've ever seen anything like it in my own career. This has been VC money going into early-stage startups, it's been IPOs, it's been follow-on financing of already public companies....
Since U.S. Treasury bonds have fallen more than -20% in value, it looks like we might've seen a short-term bottom and an opportunity to profit in the bond market. Which sectors are performing well in the intermediate term, as well as those that are taking a breather in the short term....
News, Short Squeeze, Breakout and More Instantly...
Virtus LifeSci Biotech Clinical Trials Company Name:
BBC Stock Symbol:
NYSE Market:
2024-07-09 22:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-10 01:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 08:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...